Watchdogs last week gave the green light for pembrolizumab after studies suggested patients with Hodgkin's lymphoma on it lived longer than those given radiotherapy and chemotherapy. Read this story
Watchdogs last week gave the green light for pembrolizumab after studies suggested patients with Hodgkin's lymphoma on it lived longer than those given radiotherapy and chemotherapy. Read this story
More from dailym.ai | dailymail health Cancer NHS New York